RESULTS:
Each patients’ response to treatment was unique. P1 had a complete response beginning with the third dose of the treatment. P2 showed a partial response to the treatment after the second dose. Despite 8 doses of the treatment, P3 did not achieve remission. All patients’ serum AAT levels were in normal ranges before the treatment. Only P1’s serum AAT level increased gradually and was found to be the highest after the final dose. Other patients’ serum AAT levels didn’t change during treatment. (Table 4) Distinctly, there was an increase in the proportion of CD4+ CD25+FoxP3+ lymphocytes in all of the patients.